Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Classic Hodgkin Lymphoma

Trial Profile

Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Classic Hodgkin Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Aug 2018

At a glance

  • Drugs Bendamustine (Primary) ; CPI 613 (Primary)
  • Indications Hodgkin's disease; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Jun 2018 Planned End Date changed from 1 Jan 2020 to 1 Jul 2020.
    • 29 Jun 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jan 2019.
    • 20 Dec 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top